Body’s ibuprofen, SPARC, reduces inflammation and thus bladder cancer development and metastasis
January 16, 2013 · Comments Off
A University of Colorado Cancer Center study published today in the Journal of Clinical Investigation shows that the protein SPARC (Secreted Protein Acidic and Rich in Cysteine) acts much like an anti-inflammatory drug, attempting to heal tissues inflamed by tumors. Likewise, cancers – for example, bladder cancer in this study – have developed ways to turn off the production of SPARC, thus allowing growth and metastasis, especially to the lung where bladder cancer is frequently fatal.
Follow us on Twitter 2990 followers
Connect on Facebook 118 fans
alk drug lung cancer ALL amc cancer fund American Association for Cancer Research andrew thorburn anthony elias antonio jimeno arnold levinson biomarkers bladder cancer breast cancer cancer grants cancer research colorado Cancer Survivorship CICL clinical trial colorado cancer benefit colorectal cancer crizotinib Dan Theodorescu fred hirsch funding opportunity grant head-and-neck cancer james degregori leukemia lung cancer lung cancer research melanoma metastasis microRNA Monique Spillman paul bunn prostate cancer publications rajesh agarwal ross camidge screening skin cancer Thomas Flaig tim byers university of colorado cancer center university of colorado hospital university of colorado school of medicine wells messersmith
